The FTSE 100 fell 0.3% to 10,341 as GSK weighed on the index after announcing a $10.6 billion plan to acquire shares of US drug developer Nuvalent. The move is negative for GSK in the near term due to acquisition-related pressure, though the broader market impact appears limited and mostly index-specific.
The FTSE 100 fell 0.3% to 10,341 as GSK weighed on the index after announcing a $10.6 billion plan to acquire shares of US drug developer Nuvalent. The move is negative for GSK in the near term due to acquisition-related pressure, though the broader market impact appears limited and mostly index-specific.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
